Boston Biotech Clinical Research

Boston Biotech Clinical Research (BBCR) is a specialized clinical research consultancy based in London, UK, focused exclusively on the orphan drug and rare disease sector. The company provides strategic, regulatory, and operational consulting services to biotech sponsors and investors, aiming to simplify clinical development, reduce costs, and accelerate time-to-market through its proprietary Strategic Clinical Innovation Organization (SCIO) methodology. BBCR's expertise spans early-stage development, including pre-IND strategy, protocol design, and trial rescue, with a strong focus on advanced therapy modalities like cell and gene therapy. It operates as a private, service-oriented firm, generating revenue through its consultancy offerings.

Proprietary Strategic Clinical Innovation Organization (SCIO) methodology: a process-oriented framework for developing cost-effective, de-risked clinical and regulatory strategies for orphan drugs, implemented from pre-IND through to market planning.

BBCR competes with the strategic consulting divisions of large, global Contract Research Organizations (CROs), other niche rare disease and regulatory strategy consultancies, and independent freelance experts. Its differentiation lies in its exclusive focus on orphan drugs, proprietary SCIO methodology, and tailored support for small biotechs and investors in the complex cell/gene therapy space.